Literature DB >> 12767648

Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study.

Jörg Carlsson1, Sinisa Miketic, Jürgen Windeler, Alessandro Cuneo, Sebastian Haun, Stefan Micus, Sabine Walter, Ulrich Tebbe.   

Abstract

OBJECTIVES: This study was designed to compare two treatment strategies in patients with atrial fibrillation(AF): rhythm-control (restoration and maintenance of sinus rhythm) and rate-control (pharmacologic or invasive rate-control and anticoagulation).
BACKGROUND: Atrial fibrillation is the most common arrhythmia. It is unclear whether a strategy of rhythm- or rate-control is better in terms of mortality, morbidity, and quality of life.
METHODS: The Strategies of Treatment of Atrial Fibrillation (STAF) multicenter pilot trial randomized 200 patients (100 per group) with persistent AF to rhythm- or rate-control. The combined primary end point was a combination of death, cardiopulmonary resuscitation, cerebrovascular event, and systemic embolism.
RESULTS: After 19.6 +/- 8.9 months (range 0 to 36 months) there was no difference in the primary end point between rhythm-control (9/100; 5.54%/year) and rate-control (10/100; 6.09%/year; p = 0.99). The percentage of patients in sinus rhythm in the rhythm-control group after up to four cardioversions during the follow-up period (rate-control group) was 23% (0%) at 36 months. Eighteen primary end points occurred in atrial fibrillation; only one occurred in sinus rhythm (p = 0.049).
CONCLUSIONS: The STAF pilot study showed no differences between the two treatment strategies in all end points except hospitalizations. These data suggest that there was no benefit in attempting rhythm-control in these patients with a high risk of arrhythmia recurrence. It remains unclear whether the results in the rhythm-control group would have been better if sinus rhythm had been maintained in a higher proportion of patients, as all but one end point occurred during AF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767648     DOI: 10.1016/s0735-1097(03)00332-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  184 in total

Review 1.  Atrial fibrillation (chronic).

Authors:  Deirdre A Lane; Stavros Apostolakis; Christopher J Boos; Gregory Y H Lip
Journal:  BMJ Clin Evid       Date:  2011-11-10

Review 2.  Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation.

Authors:  Vincent E Hagens; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C van Gelder
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-04       Impact factor: 1.468

3.  Management of atrial fibrillation. Rhythm or rate? That is the question.

Authors:  Sharon K Bal; Charles Czarnowski
Journal:  Can Fam Physician       Date:  2003-11       Impact factor: 3.275

Review 4.  Randomized trials of rate vs. rhythm control for atrial fibrillation.

Authors:  Mina K Chung
Journal:  J Interv Card Electrophysiol       Date:  2004       Impact factor: 1.900

5.  Persistent atrial fibrillation: rate control or rhythm control. Rate control is not inferior to rhythm control.

Authors:  Christopher J Boos; Ranjit S More; Jorg Carlsson
Journal:  BMJ       Date:  2003-06-28

Review 6.  Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins.

Authors:  F De Rienzo; R R Gabdoulline; R C Wade; M Sola; M C Menziani
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

Review 7.  Theory and practice of defibrillation: (1) Atrial fibrillation and DC conversion.

Authors:  A A J Adgey; S J Walsh
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

Review 8.  Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities.

Authors:  Michiel Rienstra; Steven A Lubitz; Saagar Mahida; Jared W Magnani; João D Fontes; Moritz F Sinner; Isabelle C Van Gelder; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2012-06-12       Impact factor: 29.690

Review 9.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

10.  Long-term outcomes (>2 years) of atrial fibrillation ablation using a multi-electrode ablation catheter in patients with paroxysmal atrial fibrillation.

Authors:  Khang-Li Looi; Parag Gajendragadkar; Tamer Taha; Maros Elsik; Elizabeth Scully; Patrick Heck; Simon Fynn; Munmohan Virdee; David Begley
Journal:  J Interv Card Electrophysiol       Date:  2012-10-25       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.